These findings implicated the CBX4-TFII-I-MEX-3B-lfTSLP pathway mediated allergic airway inflammation, thereby suggesting CBX4 inhibition as a potential therapeutic protocol for asthma management. The gene discussed is CBX4; the disease is asthma.